A Phase 3 interventional study of Albiglutide and Sulfonylurea in Diabetes Mellitus, sponsored by GlaxoSmithKline. Completed at 49 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-05-03.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Diabetes Mellitus by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus · GlaxoSmithKline.
Among the 38 studies in Diabetes Mellitus by GlaxoSmithKline, this one is the 8th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2013, is one of 11 in phase 3, and was the 32nd registered.
8,294 studies on the registry are indexed under Diabetes Mellitus; 1,073 are open to participants now.
Browse Diabetes Mellitus studies →None of the 38 studies in Diabetes Mellitus by GlaxoSmithKline is open now. The open studies under Diabetes Mellitus, anywhere →
Of the 650 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 89 take children under 18; 182 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 10 · Phase 3 11 · Phase 4 3
First in 2001; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 374 is above the median of 80 across 6,026 interventional studies indexed under Diabetes Mellitus.
Median enrollment 78 across the 33 interventional studies, 54,202 across the 5 observational. Of the 38 that completed or were terminated, 19 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 38 studies in Diabetes Mellitus by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to examine the long term safety and efficacy of weekly subcutaneously injected albiglutide in combination with a single oral antidiabetic drug for 52 weeks in Japanese subjects with type 2 diabetes mellitus.
This study is designed to examine the long term safety and efficacy of weekly subcutaneously injected albiglutide in combination with a single oral antidiabetic drug for 52 weeks in Japanese subjects with type 2 diabetes mellitus. Subjects with a historical diagnosis of type 2 diabetes mellitus who are inadequately controlled on a single oral antidiabetic agent will be recruited into the study. Subjects will continue on their single antidiabetic agent and once weekly albiglutide will be added.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Albiglutide in combination with background sulfonylurea
Drug: Albiglutide · Drug: Sulfonylurea
Albiglutide in combination with background biguanide
Drug: Albiglutide · Drug: Biguanide
Albiglutide in combination with background glinide
Drug: Albiglutide · Drug: Glinide
Albiglutide in combination with background thiazolidinedione
Drug: Albiglutide · Drug: Thiazolidinedione
Albiglutide in combination with background alpha-glucosidase inhibitor
Drug: Albiglutide · Drug: Alpha-glucosidase inhibitor
Albiglutide is a fixed-dose, fully disposable pen injector system for delivery of albiglutide from a prefilled dual chamber glass cartridge that is an integral part of the pen. It is intended for single use by the subject. It is designed for manual reconstitution of the dose, priming, and insertion of the pen needle, and manual injection by the subject. The subject will inject albiglutide 30 mg weekly for 52 weeks (with optional uptitration to 50 mg weekly) subcutaneously into the abdomen, alternating between left and right sides. The pen is designed to work with standard pen needles.
Drug pages: Sulfonylurea Antidiabetic Agent · N,N''-sulfonylbis-urea
Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE)
An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of non-serious AEs and SAEs. Non-serious hypoglycemia events are not included.
Time frame: From Baseline through Week 52
Number of Participants With Any Hypoglycemic Event
Hypoglycemia events are defined with respect to low plasma glucose level, mostly accompanied by typical symptoms and/or assistance needed from third party with glucose administration. These events were reported by the investigators upon verification of the plasma glucose levels, symptoms and assistance recorded by the participants, and/or plasma glucose values obtained from laboratory evaluations.
Time frame: From Baseline through Week 52
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 52
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the value at Week 52 minus the value at Baseline. Participants who discontinued from study treatment before Week 52 had their last on-treatment, post-Baseline HbA1c observation carried forward for the analysis.
Time frame: Baseline and Week 52
Percentage of Participants Achieving Clinically Meaningful Levels of HbA1c (i.e., the Percentage of Participants Achieving Treatment Goal of <6.5% and <7.0% at Week 52)
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3 month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Participants who discontinued from study treatment before Week 52 had their last on-treatment, post-Baseline HbA1c observation carried forward for the analysis. Clinically meaningful levels of response in HbA1c are defined as \<6.5% and \<7.0%.
Time frame: Week 52
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52
FPG is an indicator of efficacy. The Baseline FPG value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the FPG value at Week 52 minus the FPG value at Baseline. Participants who discontinued from study treatment before Week 52 had their last on-treatment, post-Baseline FPG observation carried forward for the analysis.
Time frame: Baseline and Week 52
Change From Baseline in Body Weight at Week 52
The Baseline body weight value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the body weight value at Week 52 minus the value at Baseline. Participants who discontinued from study treatment before Week 52 had their last on-treatment, post-Baseline weight observation carried forward for the analysis.
Time frame: Baseline and Week 52
Time to Study Withdrawal Due to Hyperglycemia
Participants who experienced persistent hyperglycemia after uptitration were to be withdrawn from the study. Hyperglycemia is defined as a fasting plasma glucose \>=280 mg/dL (\>=15.5 mmol/L) from \>=Week 2 to \<Week 12 or \>=230 mg/dL (\>=12.8 mmol/L) from \>=Week 12 to \<Week 52.
Time frame: Week 52
A total of 360 participants with type 2 diabetes mellitus (T2DM) were planned and 374 participants were enrolled and analyzed in the Safety Population; the Safety Population and Intent-to-Treat Population were identical in this study.
| Milestone | Albiglutide Plus (+) Background OAD (Sulfonylurea) | Albiglutide Plus (+) Background OAD (Biguanide) | Albiglutide Plus (+) Background OAD (Glinide) | Albiglutide Plus (+) Background OAD (Thiazolidinedione) | Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor) |
|---|---|---|---|---|---|
| Started | 120 | 67 | 65 | 61 | 61 |
| Completing treatment period | 109 | 63 | 59 | 59 | 54 |
| Completing follow-up period | 109 | 63 | 59 | 59 | 54 |
| Completed | 109 | 63 | 59 | 59 | 54 |
| Not completed | 11 | 4 | 6 | 2 | 7 |
| Withdrew: Persistent hyperglycemia | 0 | 0 | 1 | 0 | 0 |
| Withdrew: New antidiabetic medication | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 4 | 4 | 2 | 1 | 3 |
| Withdrew: Withdrawal by subject | 4 | 0 | 0 | 1 | 2 |
| Withdrew: Protocol violation | 2 | 0 | 1 | 0 | 2 |
| Withdrew: Moved, transfer abroad, did not enter fu | 1 | 0 | 1 | 0 | 0 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of non-serious AEs and SAEs. Non-serious hypoglycemia events are not included.
| Participants | Albiglutide Plus (+) Background OAD (Sulfonylurea) | Albiglutide Plus (+) Background OAD (Biguanide) | Albiglutide Plus (+) Background OAD (Glinide) | Albiglutide Plus (+) Background OAD (Thiazolidinedione) | Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor) |
|---|---|---|---|---|---|
| Any AE | 97 | 47 | 58 | 49 | 43 |
| Any SAE | 2 | 0 | 1 | 2 | 3 |
Hypoglycemia events are defined with respect to low plasma glucose level, mostly accompanied by typical symptoms and/or assistance needed from third party with glucose administration. These events were reported by the investigators upon verification of the plasma glucose levels, symptoms and assistance recorded by the participants, and/or plasma glucose values obtained from laboratory evaluations.
| Participants | Albiglutide Plus (+) Background OAD (Sulfonylurea) | Albiglutide Plus (+) Background OAD (Biguanide) | Albiglutide Plus (+) Background OAD (Glinide) | Albiglutide Plus (+) Background OAD (Thiazolidinedione) | Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor) |
|---|---|---|---|---|---|
| Number of Participants With Any Hypoglycemic Event | 17 | 1 | 4 | 2 | 0 |
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the value at Week 52 minus the value at Baseline. Participants who discontinued from study treatment before Week 52 had their last on-treatment, post-Baseline HbA1c observation carried forward for the analysis.
| Percentage of HbA1c in the blood | Albiglutide Plus (+) Background OAD (Sulfonylurea) | Albiglutide Plus (+) Background OAD (Biguanide) | Albiglutide Plus (+) Background OAD (Glinide) | Albiglutide Plus (+) Background OAD (Thiazolidinedione) | Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor) |
|---|---|---|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 52 | -1.04 ± 0.657 | -0.94 ± 0.623 | -0.95 ± 0.836 | -1.42 ± 0.771 | -1.39 ± 0.770 |
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3 month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Participants who discontinued from study treatment before Week 52 had their last on-treatment, post-Baseline HbA1c observation carried forward for the analysis. Clinically meaningful levels of response in HbA1c are defined as \<6.5% and \<7.0%.
| Percentage of participants | Albiglutide Plus (+) Background OAD (Sulfonylurea) | Albiglutide Plus (+) Background OAD (Biguanide) | Albiglutide Plus (+) Background OAD (Glinide) | Albiglutide Plus (+) Background OAD (Thiazolidinedione) | Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor) |
|---|---|---|---|---|---|
| HbA1c <6.5% | 20.0 | 26.9 | 24.6 | 45.9 | 26.2 |
| HbA1c <7.0% | 54.2 | 59.7 | 52.3 | 80.3 | 67.2 |
FPG is an indicator of efficacy. The Baseline FPG value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the FPG value at Week 52 minus the FPG value at Baseline. Participants who discontinued from study treatment before Week 52 had their last on-treatment, post-Baseline FPG observation carried forward for the analysis.
| Milligrams per deciliter (mg/dL) | Albiglutide Plus (+) Background OAD (Sulfonylurea) | Albiglutide Plus (+) Background OAD (Biguanide) | Albiglutide Plus (+) Background OAD (Glinide) | Albiglutide Plus (+) Background OAD (Thiazolidinedione) | Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor) |
|---|---|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52 | -16.4 ± 28.52 | -24.3 ± 19.98 | -16.4 ± 30.37 | -32.1 ± 27.21 | -33.2 ± 28.38 |
The Baseline body weight value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the body weight value at Week 52 minus the value at Baseline. Participants who discontinued from study treatment before Week 52 had their last on-treatment, post-Baseline weight observation carried forward for the analysis.
| Kilograms (kg) | Albiglutide Plus (+) Background OAD (Sulfonylurea) | Albiglutide Plus (+) Background OAD (Biguanide) | Albiglutide Plus (+) Background OAD (Glinide) | Albiglutide Plus (+) Background OAD (Thiazolidinedione) | Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor) |
|---|---|---|---|---|---|
| Change From Baseline in Body Weight at Week 52 | 0.25 ± 2.167 | -0.33 ± 2.082 | -0.04 ± 2.405 | 0.52 ± 2.823 | -0.13 ± 2.620 |
Participants who experienced persistent hyperglycemia after uptitration were to be withdrawn from the study. Hyperglycemia is defined as a fasting plasma glucose \>=280 mg/dL (\>=15.5 mmol/L) from \>=Week 2 to \<Week 12 or \>=230 mg/dL (\>=12.8 mmol/L) from \>=Week 12 to \<Week 52.
| Weeks | Albiglutide Plus (+) Background OAD (Sulfonylurea) | Albiglutide Plus (+) Background OAD (Biguanide) | Albiglutide Plus (+) Background OAD (Glinide) | Albiglutide Plus (+) Background OAD (Thiazolidinedione) | Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor) |
|---|---|---|---|---|---|
| Time to Study Withdrawal Due to Hyperglycemia | 13.0 ± NA | — | 16.5 ± 3.54 | — | — |
Collected over On-therapy non-serious adverse events (AEs) and serious adverse events (SAEs) with an onset date on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Albiglutide Plus (+) Background OAD (Sulfonylurea) | — | 2/120 (1.7%) | 68/120 (56.7%) |
| Albiglutide Plus (+) Background OAD (Biguanide) | — | 0/67 (0%) | 31/67 (46.3%) |
| Albiglutide Plus (+) Background OAD (Glinide) | — | 1/65 (1.5%) | 38/65 (58.5%) |
| Albiglutide Plus (+) Background OAD (Thiazolidinedione) | — | 2/61 (3.3%) | 35/61 (57.4%) |
| Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor) | — | 3/61 (4.9%) | 24/61 (39.3%) |
| Event | Albiglutide Plus (+) Background OAD (Sulfonylurea) | Albiglutide Plus (+) Background OAD (Biguanide) | Albiglutide Plus (+) Background OAD (Glinide) | Albiglutide Plus (+) Background OAD (Thiazolidinedione) | Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor) |
|---|---|---|---|---|---|
| Femur fractureInjury, poisoning and procedural complications | 0/120 | 0/67 | 0/65 | 0/61 | 1/61 |
| Foot fractureInjury, poisoning and procedural complications | 0/120 | 0/67 | 0/65 | 1/61 | 0/61 |
| Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/120 | 0/67 | 0/65 | 1/61 | 0/61 |
| Chest discomfortGeneral disorders | 0/120 | 0/67 | 0/65 | 0/61 | 1/61 |
| CholelithiasisHepatobiliary disorders | 0/120 | 0/67 | 0/65 | 0/61 | 1/61 |
| Colon AdenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/120 | 0/67 | 1/65 | 0/61 | 0/61 |
| Anal abscessInfections and infestations | 1/120 | 0/67 | 0/65 | 0/61 | 0/61 |
| Urinary tract infectionInfections and infestations | 1/120 | 0/67 | 0/65 | 0/61 | 0/61 |
| Event | Albiglutide Plus (+) Background OAD (Sulfonylurea) | Albiglutide Plus (+) Background OAD (Biguanide) | Albiglutide Plus (+) Background OAD (Glinide) | Albiglutide Plus (+) Background OAD (Thiazolidinedione) | Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor) |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 37/120 | 19/67 | 30/65 | 19/61 | 17/61 |
| HypoglycaemiaMetabolism and nutrition disorders | 17/120 | 1/67 | 4/65 | 2/61 | 0/61 |
| ConstipationGastrointestinal disorders | 15/120 | 1/67 | 4/65 | 5/61 | 2/61 |
| DiarrhoeaGastrointestinal disorders | 3/120 | 6/67 | 1/65 | 0/61 | 2/61 |
| Diabetic retinopathyEye disorders | 8/120 | 3/67 | 0/65 | 5/61 | 4/61 |
| Back painMusculoskeletal and connective tissue disorders | 4/120 | 2/67 | 1/65 | 5/61 | 0/61 |
| ContusionInjury, poisoning and procedural complications | 8/120 | 0/67 | 1/65 | 0/61 | 0/61 |
| PharyngitisInfections and infestations | 4/120 | 2/67 | 2/65 | 4/61 | 2/61 |
| BronchitisInfections and infestations | 4/120 | 4/67 | 1/65 | 2/61 | 3/61 |
| GastroenteritisInfections and infestations | 6/120 | 1/67 | 2/65 | 2/61 | 0/61 |
| Age, Continuous(Years) | Albiglutide Plus (+) Background OAD (Sulfonylurea) | Albiglutide Plus (+) Background OAD (Biguanide) | Albiglutide Plus (+) Background OAD (Glinide) | Albiglutide Plus (+) Background OAD (Thiazolidinedione) | Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor) | Total |
|---|---|---|---|---|---|---|
| Mean | 58.5 ± 9.19 | 57.0 ± 8.55 | 55.7 ± 11.07 | 59.0 ± 10.54 | 57.4 ± 10.47 | 57.7 ± 9.89 |
| Sex: Female, Male(Participants) | Albiglutide Plus (+) Background OAD (Sulfonylurea) | Albiglutide Plus (+) Background OAD (Biguanide) | Albiglutide Plus (+) Background OAD (Glinide) | Albiglutide Plus (+) Background OAD (Thiazolidinedione) | Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor) | Total |
|---|---|---|---|---|---|---|
| Female | 33 | 22 | 22 | 11 | 20 | 108 |
| Male | 87 | 45 | 43 | 50 | 41 | 266 |
| Race/Ethnicity, Customized(Participants) | Albiglutide Plus (+) Background OAD (Sulfonylurea) | Albiglutide Plus (+) Background OAD (Biguanide) | Albiglutide Plus (+) Background OAD (Glinide) | Albiglutide Plus (+) Background OAD (Thiazolidinedione) | Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor) | Total |
|---|---|---|---|---|---|---|
| Asian - Japanese Heritage | 120 | 67 | 65 | 61 | 61 | 374 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Feb 2013 to primary completion in Jan 2015, 23 months.
Results were first posted in Oct 2015, 8 months after primary completion.
Of 167 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's 23 months is above that.
Counting every sponsor, half of 230 studies reached it within 19 months; a quarter within 13 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sulfonylurea Antidiabetic Agent · N,N''-sulfonylbis-urea · Biguanides · 2,4-thiazolidinedione · Alpha-glucosidase inhibitors